This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK, June 3, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today announced a change in the Company's presentation time at the 2013 Jefferies Global Healthcare Conference being held in New York City. President and CEO, Gary S. Jacob, Ph.D., will present on Thursday, June 6, 2013, at 1:30 p.m. (ET) at the Grand Hyatt New York.
Live audio webcast of the presentation will be available under the investor relations section of Synergy's website at
www.synergypharma.com . A replay of the presentation will also be available and archived on the site for 60 days.
About Synergy Pharmaceuticals, Inc.
Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal (GI) diseases and disorders. Synergy's lead proprietary drug candidate, plecanatide, is a synthetic analog of the human GI hormone, uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a positive Phase I study of plecanatide in healthy volunteers, a positive Phase IIa and a large multicenter clinical trial in patients with chronic idiopathic constipation. Synergy is also developing plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C), having initiated the first trial in IBS-C patients in late 2012. Synergy's second GC-C agonist, SP-333, is in clinical development to treat inflammatory bowel diseases, and has recently completed its first Phase I trial in healthy volunteers. More information is available at
CONTACT: Media Contact: